Clinical Trial Search

Primary: Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples…

Primary: Number of Participants With Adverse Events — 94; 174; 76; 143 Participants

Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants

Primary: Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12 — 5.80; -6.04 cells/mm^2 — p=0.8400

Primary: Change in Weight — -2.0021; -1.5490 kg. (killograms)

Primary: Change in Weight — 9.2; 6.6 lbs

Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 98.1 percentage of participants

Primary: Annual Relapse Rate (ARR) — 0.290; 0.354 Relapses per year — p=0.3118

Primary: Composite of Severe Neonatal Morbidity and Perinatal Mortality — 164; 132 Participants — p=0.049

Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants

Primary: The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk…

Primary: Average Percent Hemoglobin (HbA) Decrement Per Day — 0.629; 0.659 %HbA per day — p=0.95

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Incidence Rates of Intussusceptions (IS) Among the HRV Cohort and Comparator Cohorts — 0.021; 0.022; 0.021; 0.028 Incidences/Person-Month

Primary: 2 - Year Progression Free Survival — 46 Participants